Skip to main content

Market Overview

Recap: Jaguar Health Q1 Earnings



Shares of Jaguar Health (NASDAQ:JAGX) decreased 1.6% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 83.93% year over year to ($0.09), which missed the estimate of ($0.02).

Revenue of $1,241,000 higher by 42.81% from the same period last year, which missed the estimate of $7,400,000.


Earnings guidance hasn't been issued by the company for now.

Jaguar Health hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: May 17, 2021

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $4.47

52-week low: $0.18

Price action over last quarter: down 36.87%

Related content: Benzinga's Full Guidance Calendar

Company Profile

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.


Related Articles (JAGX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at